| Analysis | Metabolite Name | Measured Value | Units | Gender | Glycemic status | Neuropathy |
|---|---|---|---|---|---|---|
| Reversed phase NEGATIVE ION MODE | ZEATIN [ISTD] (M+CL)- | 160111 | Peak area normalized | male | Pre-diabetic | no neuropathy |
| Reversed phase NEGATIVE ION MODE | ZEATIN [ISTD] (M+CL)- | 426866 | Peak area normalized | male | Diabetic | no neuropathy |
| Reversed phase NEGATIVE ION MODE | ZEATIN [ISTD] (M+CL)- | 477922 | Peak area normalized | female | Pre-diabetic | no neuropathy |
| Reversed phase NEGATIVE ION MODE | ZEATIN [ISTD] (M+CL)- | 499461 | Peak area normalized | female | Pre-diabetic | Neuropathy |
| Reversed phase NEGATIVE ION MODE | ZEATIN [ISTD] (M+CL)- | 506176 | Peak area normalized | male | Normoglycemic | no neuropathy |
| Reversed phase NEGATIVE ION MODE | ZEATIN [ISTD] (M+CL)- | 508077 | Peak area normalized | female | Pre-diabetic | no neuropathy |
| Reversed phase NEGATIVE ION MODE | ZEATIN [ISTD] (M+CL)- | 511367 | Peak area normalized | female | Pre-diabetic | Neuropathy |
| Reversed phase NEGATIVE ION MODE | ZEATIN [ISTD] (M+CL)- | 513971 | Peak area normalized | male | Pre-diabetic | no neuropathy |
| Reversed phase NEGATIVE ION MODE | ZEATIN [ISTD] (M+CL)- | 520041 | Peak area normalized | female | Diabetic | Neuropathy |
| Reversed phase NEGATIVE ION MODE | ZEATIN [ISTD] (M+CL)- | 521042 | Peak area normalized | male | Diabetic | Neuropathy |
| Reversed phase NEGATIVE ION MODE | ZEATIN [ISTD] (M+CL)- | 521653 | Peak area normalized | female | Diabetic | no neuropathy |
| Reversed phase NEGATIVE ION MODE | ZEATIN [ISTD] (M+CL)- | 524394 | Peak area normalized | male | Normoglycemic | no neuropathy |
| Reversed phase NEGATIVE ION MODE | ZEATIN [ISTD] (M+CL)- | 525060 | Peak area normalized | male | Diabetic | no neuropathy |
| Reversed phase NEGATIVE ION MODE | ZEATIN [ISTD] (M+CL)- | 525256 | Peak area normalized | female | Diabetic | no neuropathy |
| Reversed phase NEGATIVE ION MODE | ZEATIN [ISTD] (M+CL)- | 526382 | Peak area normalized | male | Diabetic | Neuropathy |
| Reversed phase NEGATIVE ION MODE | ZEATIN [ISTD] (M+CL)- | 526784 | Peak area normalized | female | Diabetic | Neuropathy |
| Reversed phase NEGATIVE ION MODE | ZEATIN [ISTD] (M+CL)- | 528722 | Peak area normalized | male | Normoglycemic | Neuropathy |
| Reversed phase NEGATIVE ION MODE | ZEATIN [ISTD] (M+CL)- | 528756 | Peak area normalized | male | Normoglycemic | Neuropathy |
| Reversed phase NEGATIVE ION MODE | ZEATIN [ISTD] (M+CL)- | 529678 | Peak area normalized | male | Diabetic | no neuropathy |
| Reversed phase NEGATIVE ION MODE | ZEATIN [ISTD] (M+CL)- | 530633 | Peak area normalized | female | Pre-diabetic | no neuropathy |
| Reversed phase NEGATIVE ION MODE | ZEATIN [ISTD] (M+CL)- | 534553 | Peak area normalized | male | Diabetic | Neuropathy |
| Reversed phase NEGATIVE ION MODE | ZEATIN [ISTD] (M+CL)- | 535387 | Peak area normalized | male | Pre-diabetic | Neuropathy |
| Reversed phase NEGATIVE ION MODE | ZEATIN [ISTD] (M+CL)- | 543602 | Peak area normalized | female | Pre-diabetic | Neuropathy |
| Reversed phase NEGATIVE ION MODE | ZEATIN [ISTD] (M+CL)- | 553149 | Peak area normalized | female | Pre-diabetic | no neuropathy |
| Reversed phase NEGATIVE ION MODE | ZEATIN [ISTD] (M+CL)- | 553423 | Peak area normalized | male | Pre-diabetic | Neuropathy |
| Reversed phase NEGATIVE ION MODE | ZEATIN [ISTD] (M+CL)- | 561228 | Peak area normalized | female | Pre-diabetic | Neuropathy |
| Reversed phase NEGATIVE ION MODE | ZEATIN [ISTD] (M-H)- | 59399 | Peak area normalized | male | Pre-diabetic | no neuropathy |
| Reversed phase NEGATIVE ION MODE | ZEATIN [ISTD] (M-H)- | 157391 | Peak area normalized | female | Pre-diabetic | no neuropathy |
| Reversed phase NEGATIVE ION MODE | ZEATIN [ISTD] (M-H)- | 157614 | Peak area normalized | male | Pre-diabetic | no neuropathy |
| Reversed phase NEGATIVE ION MODE | ZEATIN [ISTD] (M-H)- | 161469 | Peak area normalized | female | Pre-diabetic | Neuropathy |
| Reversed phase NEGATIVE ION MODE | ZEATIN [ISTD] (M-H)- | 166498 | Peak area normalized | male | Diabetic | no neuropathy |
| Reversed phase NEGATIVE ION MODE | ZEATIN [ISTD] (M-H)- | 166679 | Peak area normalized | male | Pre-diabetic | Neuropathy |
| Reversed phase NEGATIVE ION MODE | ZEATIN [ISTD] (M-H)- | 171346 | Peak area normalized | female | Pre-diabetic | Neuropathy |
| Reversed phase NEGATIVE ION MODE | ZEATIN [ISTD] (M-H)- | 173533 | Peak area normalized | male | Diabetic | Neuropathy |
| Reversed phase NEGATIVE ION MODE | ZEATIN [ISTD] (M-H)- | 174931 | Peak area normalized | female | Pre-diabetic | no neuropathy |
| Reversed phase NEGATIVE ION MODE | ZEATIN [ISTD] (M-H)- | 178244 | Peak area normalized | male | Normoglycemic | no neuropathy |
| Reversed phase NEGATIVE ION MODE | ZEATIN [ISTD] (M-H)- | 182030 | Peak area normalized | female | Diabetic | no neuropathy |
| Reversed phase NEGATIVE ION MODE | ZEATIN [ISTD] (M-H)- | 182322 | Peak area normalized | female | Diabetic | Neuropathy |
| Reversed phase NEGATIVE ION MODE | ZEATIN [ISTD] (M-H)- | 184599 | Peak area normalized | male | Pre-diabetic | Neuropathy |
| Reversed phase NEGATIVE ION MODE | ZEATIN [ISTD] (M-H)- | 185546 | Peak area normalized | male | Normoglycemic | no neuropathy |
| Reversed phase NEGATIVE ION MODE | ZEATIN [ISTD] (M-H)- | 187055 | Peak area normalized | male | Diabetic | no neuropathy |
| Reversed phase NEGATIVE ION MODE | ZEATIN [ISTD] (M-H)- | 187694 | Peak area normalized | female | Pre-diabetic | no neuropathy |
| Reversed phase NEGATIVE ION MODE | ZEATIN [ISTD] (M-H)- | 189846 | Peak area normalized | male | Diabetic | Neuropathy |
| Reversed phase NEGATIVE ION MODE | ZEATIN [ISTD] (M-H)- | 190550 | Peak area normalized | female | Diabetic | Neuropathy |
| Reversed phase NEGATIVE ION MODE | ZEATIN [ISTD] (M-H)- | 191760 | Peak area normalized | male | Diabetic | no neuropathy |
| Reversed phase NEGATIVE ION MODE | ZEATIN [ISTD] (M-H)- | 194083 | Peak area normalized | male | Diabetic | Neuropathy |
| Reversed phase NEGATIVE ION MODE | ZEATIN [ISTD] (M-H)- | 197455 | Peak area normalized | male | Normoglycemic | Neuropathy |
| Reversed phase NEGATIVE ION MODE | ZEATIN [ISTD] (M-H)- | 198286 | Peak area normalized | female | Pre-diabetic | Neuropathy |
| Reversed phase NEGATIVE ION MODE | ZEATIN [ISTD] (M-H)- | 205276 | Peak area normalized | female | Diabetic | no neuropathy |
| Reversed phase NEGATIVE ION MODE | ZEATIN [ISTD] (M-H)- | 212195 | Peak area normalized | female | Pre-diabetic | Neuropathy |
| Reversed phase NEGATIVE ION MODE | ZEATIN [ISTD] (M-H)- | 219109 | Peak area normalized | male | Normoglycemic | Neuropathy |
| Reversed phase NEGATIVE ION MODE | ZEATIN [ISTD] (M-H)- | 220647 | Peak area normalized | female | Pre-diabetic | no neuropathy |
| Reversed phase POSITIVE ION MODE | ZEATIN [ISTD] (M+H)+ | 1452685 | Peak area normalized | male | Pre-diabetic | no neuropathy |
| Reversed phase POSITIVE ION MODE | ZEATIN [ISTD] (M+H)+ | 1480622 | Peak area normalized | male | Pre-diabetic | Neuropathy |
| Reversed phase POSITIVE ION MODE | ZEATIN [ISTD] (M+H)+ | 1511219 | Peak area normalized | male | Diabetic | no neuropathy |
| Reversed phase POSITIVE ION MODE | ZEATIN [ISTD] (M+H)+ | 1741951 | Peak area normalized | male | Diabetic | no neuropathy |
| Reversed phase POSITIVE ION MODE | ZEATIN [ISTD] (M+H)+ | 1882261 | Peak area normalized | male | Diabetic | no neuropathy |
| Reversed phase POSITIVE ION MODE | ZEATIN [ISTD] (M+H)+ | 1936449 | Peak area normalized | male | Pre-diabetic | Neuropathy |
| Reversed phase POSITIVE ION MODE | ZEATIN [ISTD] (M+H)+ | 1989631 | Peak area normalized | male | Diabetic | Neuropathy |
| Reversed phase POSITIVE ION MODE | ZEATIN [ISTD] (M+H)+ | 1993993 | Peak area normalized | female | Pre-diabetic | no neuropathy |
| Reversed phase POSITIVE ION MODE | ZEATIN [ISTD] (M+H)+ | 1995405 | Peak area normalized | female | Pre-diabetic | Neuropathy |
| Reversed phase POSITIVE ION MODE | ZEATIN [ISTD] (M+H)+ | 1998418 | Peak area normalized | male | Diabetic | Neuropathy |
| Reversed phase POSITIVE ION MODE | ZEATIN [ISTD] (M+H)+ | 2001990 | Peak area normalized | female | Pre-diabetic | no neuropathy |
| Reversed phase POSITIVE ION MODE | ZEATIN [ISTD] (M+H)+ | 2005149 | Peak area normalized | female | Pre-diabetic | Neuropathy |
| Reversed phase POSITIVE ION MODE | ZEATIN [ISTD] (M+H)+ | 2006269 | Peak area normalized | female | Diabetic | Neuropathy |
| Reversed phase POSITIVE ION MODE | ZEATIN [ISTD] (M+H)+ | 2014434 | Peak area normalized | female | Diabetic | no neuropathy |
| Reversed phase POSITIVE ION MODE | ZEATIN [ISTD] (M+H)+ | 2015106 | Peak area normalized | male | Normoglycemic | no neuropathy |
| Reversed phase POSITIVE ION MODE | ZEATIN [ISTD] (M+H)+ | 2016589 | Peak area normalized | female | Pre-diabetic | no neuropathy |
| Reversed phase POSITIVE ION MODE | ZEATIN [ISTD] (M+H)+ | 2018552 | Peak area normalized | male | Pre-diabetic | no neuropathy |
| Reversed phase POSITIVE ION MODE | ZEATIN [ISTD] (M+H)+ | 2024149 | Peak area normalized | female | Pre-diabetic | Neuropathy |
| Reversed phase POSITIVE ION MODE | ZEATIN [ISTD] (M+H)+ | 2045454 | Peak area normalized | male | Normoglycemic | Neuropathy |
| Reversed phase POSITIVE ION MODE | ZEATIN [ISTD] (M+H)+ | 2046823 | Peak area normalized | female | Pre-diabetic | Neuropathy |
| Reversed phase POSITIVE ION MODE | ZEATIN [ISTD] (M+H)+ | 2053407 | Peak area normalized | female | Pre-diabetic | no neuropathy |
| Reversed phase POSITIVE ION MODE | ZEATIN [ISTD] (M+H)+ | 2067702 | Peak area normalized | male | Normoglycemic | no neuropathy |
| Reversed phase POSITIVE ION MODE | ZEATIN [ISTD] (M+H)+ | 2070118 | Peak area normalized | male | Normoglycemic | Neuropathy |
| Reversed phase POSITIVE ION MODE | ZEATIN [ISTD] (M+H)+ | 2074482 | Peak area normalized | male | Diabetic | Neuropathy |
| Reversed phase POSITIVE ION MODE | ZEATIN [ISTD] (M+H)+ | 2079636 | Peak area normalized | female | Diabetic | no neuropathy |
| Reversed phase POSITIVE ION MODE | ZEATIN [ISTD] (M+H)+ | 2117730 | Peak area normalized | female | Diabetic | Neuropathy |
- UCSD Metabolomics Workbench, a resource sponsored by the Common Fund of the National Institutes of Health
|